A PHASE 3, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ROMOSOZUMAB COMPARED WITH BISPHOSPHONATES IN CHILDREN AND ADOLESCENTS WITH OSTEOGENESIS IMPERFECTA

Registry ID

20200105

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE3

Study type

INTERVENTIONAL

Sponsor

AMGEN CANADA INC

Start date

2024-03-14

Last update

2023-06-30

Conditions

• OSTEOGENESIS IMPERFECTA

Related clinical trials

• A PHASE 2, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSERANGING STUDY TO EVALUATE THE SAFETY AND EFFICACY OF AGA2115 IN ADULTS WITH TYPE I, III, OR IV OSTEOGENESIS IMPERFECTA (OI)
• AN OPEN-LABEL, RANDOMIZED, ACTIVE-CONTROLLED, PHASE 3 STUDY OF SETRUSUMAB COMPARED WITH BISPHOSPHONATES IN PEDIATRIC SUBJECTS WITH OSTEOGENESIS IMPERFECTA TYPES I, III OR IV
• A PHASE 1B, SINGLE ASCENDING DOSE, RANDOMIZED, DOUBLE-BLIND STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND ACTIVITY OF SAR439459 IN ADULTS WITH OSTEOGENESIS IMPERFECTA
• A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2/3 STUDY TO ASSESS THE EFFICACY AND SAFETY OF SETRUSUMAB IN SUBJECTS WITH OSTEOGENESIS IMPERFECTA (OI)
• "MULTICENTER, SINGLE-ARM OPEN-LABEL EXTENSION STUDY TO ASSESS LONG-TERM SAFETY AND EFFICACY OF CURRENT OR PRIOR TREATMENT WITH DENOSUMAB IN CHILDREN/YOUNG ADULTS WITH OSTEOGENESIS IMPERFECTA
• A PHASE 2B, MULTICENTRE, MULTINATIONAL, PLACEBO-CONTROLLED, DOUBLE-BLIND, DOSE-FINDING STUDY IN ADULT PATIENTS WITH TYPE I, III OR IV OSTEOGENESIS IMPERFECTA TREATED WITH BPS804

View on source registry